The following information is exclusively reserved for physicians practicing in the United Kingdom where the Zio™ XT ECG monitoring service is currently authorised and made available for use in accordance with local regulatory requirements.

Click here to see the full report
Support
Support
Search

Delivering Advance AI* to Cardiac Monitoring

Learn More
A woman smiling with a water bottle

Our goal

Helping healthcare professionals achieve a definitive diagnosis, and accelerate your patients treatment pathway

Combining our technology with expert Qualified ECG Specialists (QES) review, Zio™ Service gives clinicians the assurance of expert-level accuracy in arrhythmia detection while bringing patient care to the forefront.

Yoga woman with the Zio XT

Analysis of large data sets increase efficiency at scale

The Zio™ service can expedite comprehension of large ECG data sets with our advanced AI Zio™ ECG Utilization Service (ZEUS) System. The first deep-learned algorithm clinically proven to be as accurate as cardiologists.3-6

Learn More

Quality data, robust analysis

99% mean analysable time1

The Zio Service provides uninterrupted data and high diagnostic yield to help diagnose arrhythmias accurately the first time.

Qualified ECG Specialist (QES) review)

Data is curated and verified by Qualified ECG Specialists (QES) to generate a Zio end-of-wear report. These accurate and succinct reports give you data you can trust, so you can make the right diagnosis the first time.7-9

99.9% Clinician agreement2

The accuracy of the Zio report supports clinicians in making a fast diagnosis, the first time.
Continue the conversation
Man with child on his shoulders
*Zio™ ECG Utilization Service (ZEUS) System
  1. Source: Turakhia, M., et al. Diagnostic Utility of a Novel Leadless Arrhythmia Monitoring Device. The American Journal of Cardiology, 2013
  2. Data on file. iRhythm Technologies, 2019.
  3. Data on file. iRhythm Technologies 2020. 
  4. Hannun et al. Cardiologist-level arrhythmia detection and classification in ambulatory electrocardiograms using a deep neural network. Nat Med. 2019;25:65-69. https://doi.org/10.1038/s41591-018-0268-3
  5. Deep learned algorithm is only available in the United States, the European Union, Switzerland, the United Kingdom, and Japan. 
  6. FDA 510K clearance, CE mark, UKCA mark, and PMDA-approval.
  7. Data on file. iRhythm Technologies, 2023. 
  8. Based on the US market data using Zio ECG monitors. 
  9. Zio service provides continuous, uninterrupted recording and a comprehensive end-of-wear report.

The Zio™ service is a long-term continuous ambulatory cardiac monitoring service. It consists of the Zio™ XT that collects beat-to-beat ECG data and can be worn for up to 14 days; the Zio™ ECG Utilization Service (ZEUS) System, deep learned algorithm that detects arrhythmias. The data is reviewed and curated by a team of Qualified ECG Specialists (QES) to provide the final patient report

For indications for use, warnings & contraindications, visit here

iRhythm, Zio, Zio XT, MyZio, and ZioSuite are trademarks of iRhythm Technologies, Inc. ©2026 All rights reserved.

Zio™ XT and ZEUS are UKCA-marked (UKCA0086)

For further regulatory information, visit here

WEB0062.02

Contact Us